Adam S. Grossman - Mar 23, 2022 Form 4 Insider Report for ADMA BIOLOGICS, INC. (ADMA)

Signature
/s/ Adam S. Grossman, by Brian Lenz as Attorney-in-fact
Stock symbol
ADMA
Transactions as of
Mar 23, 2022
Transactions value $
-$73,787
Form type
4
Date filed
3/25/2022, 05:15 PM
Previous filing
Mar 9, 2022
Next filing
May 13, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADMA Common Stock Tax liability -$73.8K -50.5K -2.1% $1.46 2.36M Mar 23, 2022 Direct F1, F2, F3
holding ADMA Common Stock 1.13M Mar 23, 2022 See Footnote F4
holding ADMA Common Stock 581K Mar 23, 2022 See Footnote F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes (i) 300,000 RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 907,500 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs"), of which (x) 50% of the Time Based RSUs shall vest on December 31, 2022 ("Initial Vesting Date") and (y) 50% of the Time-Based RSUs shall vest in eight (8) equal quarterly installments over a period of two years following the Initial Vesting Date, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (iii) 577,665 unvested Milestone-Based RSUs granted on September 29, 2021, subject to milestone-based vesting conditions (the "Milestone-Based RSUs") established by the Board of Directors, upon the recommendation of the
F2 (continued from footnote 1) Compensation Committee of the Board of Directors, of which (x) 247,253 of the Milestone-Based RSUs shall become vested upon the achievement of a 15% gross margin on BIVIGAM without intermediates by the end of the fourth quarter of 2022, and (y) 330,412 of the Milestone-Based RSUs shall become vested upon the achievement of $35 million in quarterly revenues in or before the fourth quarter of 2022 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (iv) 162,893 unvested RSUs granted on February 25, 2021, of which 137,362 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 25,531 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting
F3 (continued from footnote 2) 2. person's continued service as of the applicable vesting date and 25,531 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting; (v) 50,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 361,986 shares of common stock owned by the reporting person, which reflects shares previously purchased in the open market and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.
F4 These shares are owned by Areth, LLC ("Areth"). The reporting person is a control person of Areth.
F5 These shares are owned by Hariden, LLC ("Hariden"). The reporting person is the managing member of Hariden.